{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=4", "query": { "condition": "Cervical Small Cell Carcinoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 560, "total_pages": 56, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cervical+Small+Cell+Carcinoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T05:57:22.927Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03245736", "title": "Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovary Cancer", "Cervix Cancer", "Endometrium Cancer", "Bladder Cancer", "Prostate Cancer", "Esophagus Cancer", "Lung Cancer, Nonsmall Cell", "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Tisotumab Vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2017-08-23", "completion_date": "2019-01-10", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03245736" }, { "nct_id": "NCT07807345", "title": "Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head & Neck Squamous Cell Carcinoma", "Non-Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Colorectal Cancer", "Endometrial Cancer", "Urothelial Carcinoma (UC)", "Breast Cancer" ], "interventions": [ { "name": "STRO-006", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sutro Biopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 285, "start_date": "2026-09-14", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-08", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 7, "location_summary": "La Jolla, California • Orlando, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Irving", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07807345" }, { "nct_id": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2 Positive Solid Tumors" ], "interventions": [ { "name": "SBT6050", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Silverback Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2020-07-27", "completion_date": "2022-12", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460456" }, { "nct_id": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rovalpituzumab Tesirine", "type": "DRUG" }, { "name": "ABBV-181", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 182, "start_date": "2016-12-14", "completion_date": "2022-03-29", "has_results": false, "last_update_posted_date": "2022-04-14", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 5, "location_summary": "La Jolla, California • Chicago, Illinois • Huntersville, North Carolina + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03000257" }, { "nct_id": "NCT05647122", "title": "First in Human Study of AZD9592 in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumours", "Carcinoma Non-small Cell Lung", "Head and Neck Neoplasms", "Colorectal Neoplasms" ], "interventions": [ { "name": "AZD9592", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 190, "start_date": "2022-12-21", "completion_date": "2028-08-03", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 15, "location_summary": "Duarte, California • North Haven, Connecticut • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "North Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05647122" }, { "nct_id": "NCT06147037", "title": "A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Colorectal Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "FPI-2053", "type": "DRUG" }, { "name": "[111In]-FPI-2107", "type": "DRUG" }, { "name": "[225Ac]-FPI-2068", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 13, "start_date": "2024-07-31", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 6, "location_summary": "Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06147037" }, { "nct_id": "NCT04215978", "title": "Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Nasopharyngeal Carcinoma (NPC)" ], "interventions": [ { "name": "BGB-A445", "type": "DRUG" }, { "name": "tislelizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 204, "start_date": "2020-01-30", "completion_date": "2025-01-24", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 3, "location_summary": "Los Angeles, California • San Diego, California • Pittsburgh, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04215978" }, { "nct_id": "NCT00063895", "title": "Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage IIIA Non-small Cell Lung Cancer", "Stage IIIA Ovarian Epithelial Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IIIB Ovarian Epithelial Cancer", "Stage IIIC Ovarian Epithelial Cancer", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IVA Squamous Cell Carcinoma of the Larynx", "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVA Squamous Cell Carcinoma of the Oropharynx", "Stage IVB Squamous Cell Carcinoma of the Larynx", "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVB Squamous Cell Carcinoma of the Oropharynx", "Stage IVC Squamous Cell Carcinoma of the Larynx", "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IVC Squamous Cell Carcinoma of the Oropharynx" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-09", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00063895" }, { "nct_id": "NCT07405086", "title": "Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Advanced Biliary Tract Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Renal Cell Carcinoma", "Metastatic Biliary Tract Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Immune Checkpoint Inhibitor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-06-08", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07405086" }, { "nct_id": "NCT07749586", "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "ARV-6723", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "SOC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2026-07-29", "completion_date": "2032-03-31", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-09T05:57:22.927Z", "location_count": 3, "location_summary": "Huntersville, North Carolina • San Antonio, Texas • Fairfax, Virginia", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07749586" } ] }